References

Andrea C. Skelly; Eric Chang; Jessica Bordley; Erika D. Brodt; Shelley Selph; Rongwei Fu; Yun Yu; Rebecca Holmes; Tracy Dana; Shay Stabler-Morris; Dakota Riopelle; Roger Chou

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Skelly AC, Chang E, Bordley J, et al. Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Aug. (Comparative Effectiveness Review, No. 265.)

Cover of Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms

Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms [Internet].

Show details

Contents

< Prev Next >

5References

1.: Macedo F, Ladeira K, Pinho F, et al. Bone metastases: an overview. Oncol Rev. 2017 Mar 3;11(1):321. doi: 10.4081/oncol.2017.321. PMID: 28584570. [PMC free article: PMC5444408] [PubMed: 28584570] [CrossRef]
2.: Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020 Apr;8(7):482. doi: 10.21037/atm.2020.03.55. PMID: 32395526. [PMC free article: PMC7210217] [PubMed: 32395526] [CrossRef]
3.: Challapalli A, Aziz S, Khoo V, et al. Spine and non-spine bone metastases - current controversies and future direction. Clin Oncol (R Coll Radiol). 2020 Nov;32(11):728–44. doi: 10.1016/j.clon.2020.07.010. PMID: 32747153. [PubMed: 32747153] [CrossRef]
4.: Oster G, Lamerato L, Glass AG, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013 Dec;21(12):3279–86. doi: 10.1007/s00520-013-1887-3. PMID: 23884473. [PubMed: 23884473] [CrossRef]
5.: Dharmarajan KV, Rich SE, Johnstone CA, et al. Top 10 tips palliative care clinicians should know about radiation oncology. Journal of palliative medicine. 2018;21(3):383–8. doi: 10.1089/jpm.2018.0009. PMID: 29431573. [PMC free article: PMC5915220] [PubMed: 29431573] [CrossRef]
6.: Spencer K, Parrish R, Barton R, et al. Palliative radiotherapy. Bmj. 2018 Mar 23;360:k821. doi: 10.1136/bmj.k821. PMID: 29572337. [PMC free article: PMC5865075] [PubMed: 29572337] [CrossRef]
7.: Husain ZA, Sahgal A, De Salles A, et al. Stereotactic body radiotherapy for de novo spinal metastases: systematic review. J Neurosurg Spine. 2017 Sep;27(3):295–302. doi: 10.3171/2017.1.Spine16684. PMID: 28598293. [PubMed: 28598293] [CrossRef]
8.: Myrehaug S, Sahgal A, Hayashi M, et al. Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. J Neurosurg Spine. 2017 Oct;27(4):428–35. doi: 10.3171/2017.2.Spine16976. PMID: 28708043. [PubMed: 28708043] [CrossRef]
9.: Nguyen QN, Chun SG, Chow E, et al. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019 Jun 1;5(6):872–8. doi: 10.1001/jamaoncol.2019.0192. PMID: 31021390. [PMC free article: PMC6487911] [PubMed: 31021390] [CrossRef]
10.: Rembielak A, Dennis K. The evolving practice of palliative radiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)). 2020;32(11):685–7. doi: 10.1016/j.clon.2020.08.001. PMID: 32828634. [PMC free article: PMC7439155] [PubMed: 32828634] [CrossRef]
11.: Saravana-Bawan S, David E, Sahgal A, et al. Palliation of bone metastases-exploring options beyond radiotherapy. Ann Palliat Med. 2019 Apr;8(2):168–77. doi: 10.21037/apm.2018.12.04. PMID: 30691279. [PubMed: 30691279] [CrossRef]
12.: Conti A, Acker G, Kluge A, et al. Decision making in patients with metastatic spine. The role of minimally invasive treatment modalities. Frontiers in oncology. 2019;9:915-. doi: 10.3389/fonc.2019.00915. PMID: 31608228. [PMC free article: PMC6761912] [PubMed: 31608228] [CrossRef]
13.: McCabe FJ, Jadaan MM, Byrne F, et al. Spinal metastasis: The rise of minimally invasive surgery. Surgeon. 2021 Sep 22doi: 10.1016/j.surge.2021.08.007. PMID: 34563452. [PubMed: 34563452] [CrossRef]
14.: Armstrong S, Hoskin P. Complex clinical decision-making process of re-irradiation. Clin Oncol (R Coll Radiol). 2020 Nov;32(11):688–703. doi: 10.1016/j.clon.2020.07.023. PMID: 32893056. [PubMed: 32893056] [CrossRef]
15.: De Felice F, Piccioli A, Musio D, et al. The role of radiation therapy in bone metastases management. Oncotarget. 2017 Apr 11;8(15):25691–9. doi: 10.18632/oncotarget.14823. PMID: 28148890. [PMC free article: PMC5421962] [PubMed: 28148890] [CrossRef]
16.: Ganesh V, Chan S, Raman S, et al. A review of patterns of practice and clinical guidelines in the palliative radiation treatment of uncomplicated bone metastases. Radiother Oncol. 2017 Jul;124(1):38–44. doi: 10.1016/j.radonc.2017.06.002. PMID: 28629871. [PubMed: 28629871] [CrossRef]
17.: Gupta A, Wang P, Sedhom R, et al. Physician practice variability in the use of extended-fraction radiation therapy for bone metastases: are we choosing wisely? JCO Oncol Pract. 2020 Aug;16(8):e758–e69. doi: 10.1200/jop.19.00633. PMID: 32282264. [PubMed: 32282264] [CrossRef]
18.: Santos PMG, Lapen K, Zhang Z, et al. Trends in radiation therapy for bone metastases, 2015 to 2017: choosing wisely in the era of complex radiation. Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):923–31. doi: 10.1016/j.ijrobp.2020.11.016. PMID: 33188862. [PMC free article: PMC8317587] [PubMed: 33188862] [CrossRef]
19.: Spratt DE, Mancini BR, Hayman JA, et al. Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):462–7. PMID: Pmc6844366. [PMC free article: PMC6844366] [PubMed: 29726364]
20.: Squires JE, Asad S, Varin MD, et al. Behavioral determinants of canadian radiation oncologists’ use of single fraction palliative radiation therapy for uncomplicated bone metastases. Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):374–86. doi: 10.1016/j.ijrobp.2020.09.030. PMID: 32966890. [PubMed: 32966890] [CrossRef]
21.: Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017 Jan–Feb;7(1):4–12. doi: 10.1016/j.prro.2016.08.001. PMID: 27663933. [PubMed: 27663933] [CrossRef]
22.: Sprave T, Verma V, Förster R, et al. Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial) : First results of a randomized controlled trial. Strahlenther Onkol. 2018 Oct;194(10):911–20. doi: 10.1007/s00066-018-1333-z. PMID: 29978307. [PubMed: 29978307] [CrossRef]
23.: Sprave T, Verma V, Förster R, et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2018 Aug;128(2):274–82. doi: 10.1016/j.radonc.2018.04.030. PMID: 29843899. [PubMed: 29843899] [CrossRef]
24.: Sprave T, Verma V, Förster R, et al. Quality of Life and Radiation-induced Late Toxicity Following Intensity-modulated Versus Three-dimensional Conformal Radiotherapy for Patients with Spinal Bone Metastases: Results of a Randomized Trial. Anticancer Res. 2018 Aug;38(8):4953–60. doi: 10.21873/anticanres.12813. PMID: 30061275. [PubMed: 30061275] [CrossRef]
25.: Sakr A, Hashem WB, Ebrahim N, et al. Randomized Pilot Study of 20 Gy in 5 Fractions versus 27 Gy in 3 Fractions Radiotherapy for Treating Painful Bone Metastases: A Single Institution Experience. Asian Pac J Cancer Prev. 2020 Jun 1;21(6):1807–11. doi: 10.31557/apjcp.2020.21.6.1807. PMID: 32592381. [PMC free article: PMC7568878] [PubMed: 32592381] [CrossRef]
26.: Ashworth A, Kong W, Chow E, et al. Fractionation of Palliative Radiation Therapy for Bone Metastases in Ontario: Do Practice Guidelines Guide Practice? Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):31–9. [PubMed: 26454681]
27.: Sullivan T. IOM Clinical Practice Guidelines We Can Trust — But What About the IOM? Policy & Medicine; 2018. https://www.policymed.com/2011/03/iom-clinical-practice-guidelines-we-can-trust-but-what-about-the-iom.html. Accessed January 7, 2022.
28.: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. PMID: 33782057. [PMC free article: PMC8005924] [PubMed: 33782057] [CrossRef]
29.: U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. 2015. https://www.uspreventiveservicestaskforce.org/uspstf/procedure-manual. Accessed August 25 2020.
30.: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. January 2014. Chapters available at: www.effectivehealthcare.ahrq.gov. [PubMed: 21433403]
31.: Viswanathan M, Ansari MT, Berkman ND, et al. Chapter 9: Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. January 2014. Chapters available at: www.effectivehealthcare.ahrq.gov.
32.: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.handbook.cochrane.org.
33.: Furlan AD, Malmivaara A, Chou R, et al. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976). 2015 Nov;40(21):1660–73. doi: 10.1097/BRS.0000000000001061. PMID: 26208232. [PubMed: 26208232] [CrossRef]
34.: Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol. 2012 Feb;65(2):163–78. doi: 10.1016/j.jclinepi.2011.05.008. PMID: 21959223. [PubMed: 21959223] [CrossRef]
35.: Chou R, Deyo R, Friedly J, et al. Noninvasive Treatments for Low Back Pain. Comparative Effectiveness Review No. 169. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 16-EHC004-EF. Rockville, MD: Agency for Healthcare Research and Quality; February 2016. https://effectivehealthcare.ahrq.gov/products/back-pain-treatment/research. PMID: 26985522.
36.: Skelly AC, Chou R, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update. Comparative Effectiveness Review No. 227. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No. 20-EHC009. Rockville, MD: Agency for Healthcare Research and Quality; April 2020. https://effectivehealthcare.ahrq.gov/products/noninvasive-nonpharm-pain-update/research. PMID: 32338846. [PubMed: 32338846]
37.: Skelly AC, Chou R, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review. Comparative Effectiveness Review No. 209. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No 18-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality; June 2018. https://effectivehealthcare.ahrq.gov/topics/nonpharma-treatment-pain/research-2018. PMID: 30179389. [PubMed: 30179389]
38.: Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011 Nov;64(11):1187–97. doi: 10.1016/j.jclinepi.2010.08.010. PMID: 21477993. [PubMed: 21477993] [CrossRef]
39.: Morton SC, Murad MH, O’Connor E, et al. Quantitative Synthesis—An Update. Methods Guide for Comparative Effectiveness Reviews. (Prepared by the Scientific Resource Center under Contract No. 290-2012-0004-C). AHRQ Publication No. 18-EHC007-EF. Rockville, MD: Quality AfHRa; 2018.
40.: Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–60. doi: 10.1136/bmj.327.7414.557. PMID: 12958120. [PMC free article: PMC192859] [PubMed: 12958120] [CrossRef]
41.: 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol. 1999 Aug;52(2):111–21. PMID: 10577696. [PubMed: 10577696]
42.: Atahan L, Yildiz F, Cengiz M, et al. Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. Support Care Cancer. 2010 Jun;18(6):691–8. doi: 10.1007/s00520-009-0663-x. PMID: 19484483. [PubMed: 19484483] [CrossRef]
43.: Hamouda WE, Roshdy W, Teema M. Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. Gulf J Oncolog. 2007 Jan;1(1):35–41. PMID: 20084712. [PubMed: 20084712]
44.: Majumder D, Chatterjee D, Bandyopadhyay A, et al. Single Fraction versus Multiple Fraction Radiotherapy for Palliation of Painful Vertebral Bone Metastases: A Prospective Study. Indian J Palliat Care. 2012 Sep;18(3):202–6. doi: 10.4103/0973-1075.105691. PMID: 23440009. [PMC free article: PMC3573475] [PubMed: 23440009] [CrossRef]
45.: Nielsen OS, Bentzen SM, Sandberg E, et al. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol. 1998 Jun;47(3):233–40. doi: 10.1016/s0167-8140(98)00011-5. PMID: 9681885. [PubMed: 9681885] [CrossRef]
46.: Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999 Aug;52(2):101–9. doi: 10.1016/s0167-8140(99)00110-3. PMID: 10577695. [PubMed: 10577695] [CrossRef]
47.: Lee KA, Dunne M, Small C, et al. (ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis. Acta Oncol. 2018 Jul;57(7):965–72. doi: 10.1080/0284186x.2018.1433320. PMID: 29419331. [PubMed: 29419331] [CrossRef]
48.: Chou R, Hartung D, Turner J, et al. Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No. 20-EHC011. Rockville, MD: Agency for Healthcare Research and Quality; 2020. doi: 10.23970/AHRQEPCCER229. PMID: 32338848. [CrossRef]
49.: Chou R, Wagner J, Ahmed AY, et al. Treatments for Acute Pain: A Systematic Review. Comparative Effectiveness Review No. 240. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No. 20(21)-EHC006. Rockville, MD: Agency for Healthcare Research and Quality; December 2020. doi: 10.23970/AHRQEPCCER240. PMID: 33411426. [CrossRef]
50.: Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011 Jul 22;343:d4002. doi: 10.1136/bmj.d4002. PMID: 21784880. [PubMed: 21784880] [CrossRef]
51.: Abu-Hegazy M, Wahba HA. Single-versus multi-fraction radiation treatment for metastatic spinal cord compression: functional outcome study. The Chinese-German Journal of Clinical Oncology. 2011;10(9):535–40. doi: 10.1007/s10330-011-0832-5. [CrossRef]
52.: Ahmed S, S MK, Salah T, et al. Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin. J Bone Oncol. 2021 Dec;31:100395. doi: 10.1016/j.jbo.2021.100395. PMID: 34712554. [PMC free article: PMC8529095] [PubMed: 34712554] [CrossRef]
53.: Amouzegar-Hashemi F, Behrouzi H, Kazemian A, et al. Single versus multiple fractions of palliative radiotherapy for bone metastases: a randomized clinical trial in Iranian patients. Curr Oncol. 2008 Jun;15(3):151. doi: 10.3747/co.v15i3.203. PMID: 18596887. [PMC free article: PMC2442760] [PubMed: 18596887] [CrossRef]
54.: Anter AH. Single Fraction versus Multiple Fraction Radiotherapy for treatment of painful bone metastases: A Prospective Study; Mansoura experience. Forum of Clinical Oncology. 2015;6(2):8–13. doi: 10.1515/fco-2015-0007. [CrossRef]
55.: Badzio A, Senkus-Konefka E, Jereczek-Fossa BA, et al. 20 Gy in five fractions versus 8 Gy in one fraction in palliative radiotherapy of bone metastases. A multicenter randomized study. Nowotwory. 2003;53(3):261–4. doi: https://core.ac.uk/download/pdf/268466089.pdf.
56.: Chi MS, Yang KL, Chang YC, et al. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78–87. doi: 10.1016/j.ijrobp.2017.09.030. PMID: 29066122. [PubMed: 29066122] [CrossRef]
57.: Chow E, Meyer RM, Ding K, et al. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Nov;16(15):1463–72. doi: 10.1016/S1470-2045(15)00199-0. PMID: 26489389. [PubMed: 26489389] [CrossRef]
58.: Chow E, van der Linden YM, Roos D, et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 2014 Feb;15(2):164–71. doi: 10.1016/s1470-2045(13)70556-4. PMID: 24369114. [PubMed: 24369114] [CrossRef]
59.: Foro Arnalot P, Fontanals AV, Galcerán JC, et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol. 2008 Nov;89(2):150–5. doi: 10.1016/j.radonc.2008.05.018. PMID: 18556080. [PubMed: 18556080] [CrossRef]
60.: Gaze MN, Kelly CG, Kerr GR, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol. 1997 Nov;45(2):109–16. doi: 10.1016/s0167-8140(97)00101-1. PMID: 9423999. [PubMed: 9423999] [CrossRef]
61.: Gutierrez Bayard L, Salas Buzon Mdel C, Angulo Pain E, et al. Radiation therapy for the management of painful bone metastases: Results from a randomized trial. Rep Pract Oncol Radiother. 2014 Nov;19(6):405–11. doi: 10.1016/j.rpor.2014.04.009. PMID: 25337414. [PMC free article: PMC4201774] [PubMed: 25337414] [CrossRef]
62.: Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 Jun 1;97(11):798–804. doi: 10.1093/jnci/dji139. PMID: 15928300. [PubMed: 15928300] [CrossRef]
63.: He J, Shi S, Ye L, et al. A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma. J Cancer. 2019;10(17):4031–7. doi: 10.7150/jca.28674. PMID: 31417647. [PMC free article: PMC6692619] [PubMed: 31417647] [CrossRef]
64.: Hoskin P, Rojas A, Fidarova E, et al. IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases. Radiother Oncol. 2015 Jul;116(1):10–4. doi: 10.1016/j.radonc.2015.05.008. PMID: 26026485. [PubMed: 26026485] [CrossRef]
65.: Hoskin P, Sundar S, Reczko K, et al. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. J Natl Cancer Inst. 2015 Oct;107(10):djv197. doi: 10.1093/jnci/djv197. PMID: 26242893. [PubMed: 26242893] [CrossRef]
66.: Hoskin PJ, Hopkins K, Misra V, et al. Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA. 2019 Dec 3;322(21):2084–94. doi: 10.1001/jama.2019.17913. PMID: 31794625. [PMC free article: PMC6902166] [PubMed: 31794625] [CrossRef]
67.: Hoskin PJ, Price P, Easton D, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992 Feb;23(2):74–8. doi: 10.1016/0167-8140(92)90338-u. PMID: 1372126. [PubMed: 1372126] [CrossRef]
68.: Howell DD, James JL, Hartsell WF, et al. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14. Cancer. 2013 Feb 15;119(4):888–96. doi: 10.1002/cncr.27616. PMID: 23165743. [PMC free article: PMC5746185] [PubMed: 23165743] [CrossRef]
69.: Jeremic B, Shibamoto Y, Acimovic L, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):161–7. doi: 10.1016/s0360-3016(98)00174-6. PMID: 9747834. [PubMed: 9747834] [CrossRef]
70.: Kaasa S, Brenne E, Lund JA, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. Radiother Oncol. 2006 Jun;79(3):278–84. doi: 10.1016/j.radonc.2006.05.006. PMID: 16793154. [PubMed: 16793154] [CrossRef]
71.: Konski A, Desilvio M, Hartsell W, et al. Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):229–33. doi: 10.1016/j.ijrobp.2006.04.005. PMID: 16814950. [PubMed: 16814950] [CrossRef]
72.: Mañas A, Casas F, Ciria JP, et al. Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. Clin Transl Oncol. 2008 May;10(5):281–7. doi: 10.1007/s12094-008-0198-5. PMID: 18490245. [PubMed: 18490245] [CrossRef]
73.: Maranzano E, Bellavita R, Rossi R, et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol. 2005 May 20;23(15):3358–65. doi: 10.1200/jco.2005.08.193. PMID: 15738534. [PubMed: 15738534] [CrossRef]
74.: Maranzano E, Trippa F, Casale M, et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol. 2009 Nov;93(2):174–9. doi: 10.1016/j.radonc.2009.05.012. PMID: 19520448. [PubMed: 19520448] [CrossRef]
75.: Meeuse JJ, van der Linden YM, van Tienhoven G, et al. Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life: results from the Dutch Bone Metastasis Study. Cancer. 2010 Jun 1;116(11):2716–25. doi: 10.1002/cncr.25062. PMID: 20225326. [PubMed: 20225326] [CrossRef]
76.: Niewald M, Tkocz HJ, Abel U, et al. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1085–9. doi: 10.1016/s0360-3016(96)00388-4. PMID: 8985030. [PubMed: 8985030] [CrossRef]
77.: Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013 Mar;11(1):20–6. doi: 10.1016/j.clgc.2012.07.002. PMID: 23021204. [PubMed: 23021204] [CrossRef]
78.: Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8(7):587–94. doi: 10.1016/S1470-2045(07)70147-X. PMID: 17544845. [PubMed: 17544845] [CrossRef]
79.: Nongkynrih A, Dhull AK, Kaushal V, et al. Comparison of Single Versus Multifraction Radiotherapy in Palliation of Painful Bone Metastases. World J Oncol. 2018 Jun;9(3):91–5. doi: 10.14740/wjon1118w. PMID: 29988783. [PMC free article: PMC6031233] [PubMed: 29988783] [CrossRef]
80.: Okawa T, Kita M, Goto M, et al. Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases. Radiother Oncol. 1988 Oct;13(2):99–104. doi: 10.1016/0167-8140(88)90031-x. PMID: 2462264. [PubMed: 2462264] [CrossRef]
81.: Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003 Nov;44(5):519–26. doi: 10.1016/s0302-2838(03)00364-6. PMID: 14572748. [PubMed: 14572748] [CrossRef]
82.: Özsaran Z, Yalman D, Anacak Y, et al. Palliative radiotherapy in bone metastases: Results of a randomized trial comparing three fractionation schedules. Journal of B.U.ON. 2001;6(1):43–8.
83.: Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005 Aug 20–26;366(9486):643–8. doi: 10.1016/s0140-6736(05)66954-1. PMID: 16112300. [PubMed: 16112300] [CrossRef]
84.: Pielkenrood BJ, van der Velden JM, van der Linden YM, et al. Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):358–67. doi: 10.1016/j.ijrobp.2020.11.060. PMID: 33333200. [PubMed: 33333200] [CrossRef]
85.: Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):805–13. doi: 10.1016/0360-3016(93)90309-j. PMID: 8478230. [PubMed: 8478230] [CrossRef]
86.: Poulter CA, Cosmatos D, Rubin P, et al. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys. 1992;23(1):207–14. doi: 10.1016/0360-3016(92)90563-w. PMID: 1374061. [PubMed: 1374061] [CrossRef]
87.: Price P, Hoskin PJ, Easton D, et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986 Aug;6(4):247–55. doi: 10.1016/s0167-8140(86)80191-8. PMID: 3775071. [PubMed: 3775071] [CrossRef]
88.: Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994 Apr;31(1):33–40. doi: 10.1016/0167-8140(94)90411-1. PMID: 7518932. [PubMed: 7518932] [CrossRef]
89.: Rades D, Conde-Moreno AJ, Cacicedo J, et al. Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. Anticancer Res. 2018 Feb;38(2):1009–15. doi: 10.21873/anticanres.12316. PMID: 29374734. [PubMed: 29374734] [CrossRef]
90.: Rades D, Šegedin B, Conde-Moreno AJ, et al. Patient-Reported Outcomes-Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy × 5 to 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression. Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):760–4. doi: 10.1016/j.ijrobp.2019.08.002. PMID: 31415797. [PubMed: 31415797] [CrossRef]
91.: Rades D, Šegedin B, Conde-Moreno AJ, et al. Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). J Clin Oncol. 2016 Feb 20;34(6):597–602. doi: 10.1200/jco.2015.64.0862. PMID: 26729431. [PubMed: 26729431] [CrossRef]
92.: Rasmusson B, Vejborg I, Jensen AB, et al. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother Oncol. 1995 Mar;34(3):179–84. doi: 10.1016/0167-8140(95)01520-q. PMID: 7631024. [PubMed: 7631024] [CrossRef]
93.: Roos DE, Turner SL, O’Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005 Apr;75(1):54–63. doi: 10.1016/j.radonc.2004.09.017. PMID: 15878101. [PubMed: 15878101] [CrossRef]
94.: Sahgal A, Myrehaug SD, Siva S, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021 Jul;22(7):1023–33. doi: 10.1016/s1470-2045(21)00196-0. PMID: 34126044. [PubMed: 34126044] [CrossRef]
95.: Sande TA, Ruenes R, Lund JA, et al. Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial. Radiother Oncol. 2009 May;91(2):261–6. doi: 10.1016/j.radonc.2009.02.014. PMID: 19307034. [PubMed: 19307034] [CrossRef]
96.: Sarkar SK, Sarkar S, Pahari B, et al. Multiple and single fraction palliative radiotherapy in bone secondaries - A prospective study. Indian Journal of Radiology and Imaging. 2002;12(2):281–4.
97.: Smeland S, Erikstein B, Aas M, et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1397–404. doi: 10.1016/s0360-3016(03)00274-8. PMID: 12873686. [PubMed: 12873686] [CrossRef]
98.: Sørensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994;30A(1):22–7. doi: 10.1016/s0959-8049(05)80011-5. PMID: 8142159. [PubMed: 8142159] [CrossRef]
99.: Sprave T, Verma V, Förster R, et al. Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial. Anticancer Res. 2018 Aug;38(8):4961–8. doi: 10.21873/anticanres.12814. PMID: 30061276. [PubMed: 30061276] [CrossRef]
100.: Sprave T, Verma V, Förster R, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial. Radiat Oncol. 2018 Oct 30;13(1):212. doi: 10.1186/s13014-018-1161-4. PMID: 30376859. [PMC free article: PMC6208115] [PubMed: 30376859] [CrossRef]
101.: Sprave T, Verma V, Förster R, et al. Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial. BMC Cancer. 2018 Aug 31;18(1):859. doi: 10.1186/s12885-018-4777-8. PMID: 30170568. [PMC free article: PMC6119304] [PubMed: 30170568] [CrossRef]
102.: Thirion PG, Dunne MT, Kelly PJ, et al. Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression. Br J Cancer. 2020 Apr;122(9):1315–23. doi: 10.1038/s41416-020-0768-z. PMID: 32157242. [PMC free article: PMC7188681] [PubMed: 32157242] [CrossRef]
103.: van der Linden YM, Lok JJ, Steenland E, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):528–37. doi: 10.1016/j.ijrobp.2003.10.006. PMID: 15145173. [PubMed: 15145173] [CrossRef]
104.: van der Linden YM, Steenland E, van Houwelingen HC, et al. Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiother Oncol. 2006 Mar;78(3):245–53. doi: 10.1016/j.radonc.2006.02.007. PMID: 16545474. [PubMed: 16545474] [CrossRef]
105.: Zaghloul MS, Boutrus R, El-Hossieny H, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010 Aug;15(4):382–9. doi: 10.1007/s10147-010-0074-5. PMID: 20354750. [PubMed: 20354750] [CrossRef]
106.: Zelefsky MJ, Yamada Y, Greco C, et al. Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):672–9. doi: 10.1016/j.ijrobp.2021.01.004. PMID: 33422612. [PMC free article: PMC9472455] [PubMed: 33422612] [CrossRef]
107.: Al-Omair A, Masucci L, Masson-Cote L, et al. Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy. Neuro Oncol. 2013 Oct;15(10):1413–9. doi: 10.1093/neuonc/not101. PMID: 24057886. [PMC free article: PMC3779044] [PubMed: 24057886] [CrossRef]
108.: Amini A, Altoos B, Bourlon MT, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol. 2015 Nov–Dec;5(6):e589–e96. doi: 10.1016/j.prro.2015.05.004. PMID: 26142027. [PMC free article: PMC4706456] [PubMed: 26142027] [CrossRef]
109.: Bate BG, Khan NR, Kimball BY, et al. Stereotactic radiosurgery for spinal metastases with or without separation surgery. J Neurosurg Spine. 2015 Apr;22(4):409–15. doi: 10.3171/2014.10.SPINE14252. PMID: 25635638. [PubMed: 25635638] [CrossRef]
110.: Boeri L, Sharma V, Kwon E, et al. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):514–23. doi: 10.1038/s41391-020-00307-y. PMID: 33268854. [PubMed: 33268854] [CrossRef]
111.: Conway JL, Yurkowski E, Glazier J, et al. Comparison of patient-reported outcomes with single versus multiple fraction palliative radiotherapy for bone metastasis in a population-based cohort. Radiother Oncol. 2016 May;119(2):202–7. doi: 10.1016/j.radonc.2016.03.025. PMID: 27072939. [PubMed: 27072939] [CrossRef]
112.: Di Staso M, Gravina GL, Zugaro L, et al. Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 Patients. PLoS One. 2015;10(6):e0129021. doi: 10.1371/journal.pone.0129021. PMID: 26103516. [PMC free article: PMC4478013] [PubMed: 26103516] [CrossRef]
113.: Folkert MR, Bilsky MH, Tom AK, et al. Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1085–91. doi: 10.1016/j.ijrobp.2013.12.042. PMID: 24661662. [PubMed: 24661662] [CrossRef]
114.: Ghia AJ, Chang EL, Bishop AJ, et al. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials. J Neurosurg Spine. 2016 May;24(5):829–36. doi: 10.3171/2015.8.Spine15844. PMID: 26799117. [PubMed: 26799117] [CrossRef]
115.: Guckenberger M, Sweeney RA, Hawkins M, et al. Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. Cancer. 2018 May 1;124(9):2001–9. doi: 10.1002/cncr.31294. PMID: 29499073. [PubMed: 29499073] [CrossRef]
116.: Haley ML, Gerszten PC, Heron DE, et al. Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J Neurosurg Spine. 2011 Apr;14(4):537–42. doi: 10.3171/2010.12.SPINE10233. PMID: 21314284. [PubMed: 21314284] [CrossRef]
117.: Heron DE, Rajagopalan MS, Stone B, et al. Single-session and multisession CyberKnife radiosurgery for spine metastases-University of Pittsburgh and Georgetown University experience. J Neurosurg Spine. 2012 Jul;17(1):11–8. doi: 10.3171/2012.4.Spine11902. PMID: 22578235. [PubMed: 22578235] [CrossRef]
118.: Hird A, Chow E, Zhang L, et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):193–7. doi: 10.1016/j.ijrobp.2008.10.044. PMID: 19167840. [PubMed: 19167840] [CrossRef]
119.: Hosaka S, Katagiri H, Niwakawa M, et al. Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis. Int J Clin Oncol. 2018 Dec;23(6):1127–33. doi: 10.1007/s10147-018-1310-7. PMID: 29959563. [PubMed: 29959563] [CrossRef]
120.: Kelley KD, Racareanu R, Sison CP, et al. Outcomes in the radiosurgical management of metastatic spine disease. Adv Radiat Oncol. 2019 Apr–Jun;4(2):283–93. doi: 10.1016/j.adro.2018.10.007. PMID: 31011673. [PMC free article: PMC6460302] [PubMed: 31011673] [CrossRef]
121.: Lam TC, Uno H, Krishnan M, et al. Adverse Outcomes After Palliative Radiation Therapy for Uncomplicated Spine Metastases: Role of Spinal Instability and Single-Fraction Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):373–81. doi: 10.1016/j.ijrobp.2015.06.006. PMID: 26279324. [PubMed: 26279324] [CrossRef]
122.: Loblaw DA, Wu JS, Kirkbride P, et al. Pain flare in patients with bone metastases after palliative radiotherapy--a nested randomized control trial. Support Care Cancer. 2007 Apr;15(4):451–5. doi: 10.1007/s00520-006-0166-y. PMID: 17093912. [PubMed: 17093912] [CrossRef]
123.: Ma Y, He S, Liu T, et al. Quality of Life of Patients with Spinal Metastasis from Cancer of Unknown Primary Origin: A Longitudinal Study of Surgical Management Combined with Postoperative Radiation Therapy. J Bone Joint Surg Am. 2017 Oct 4;99(19):1629–39. doi: 10.2106/jbjs.16.00286. PMID: 28976427. [PubMed: 28976427] [CrossRef]
124.: Olson RA, LaPointe V, Benny A, et al. Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System. Current oncology (Toronto, Ont.). 2022;29(3):2073–80. doi: 10.3390/curroncol29030167. PMID: 35323367. [PMC free article: PMC8947740] [PubMed: 35323367] [CrossRef]
125.: Rades D, Cacicedo J, Conde-Moreno AJ, et al. Precision Radiation Therapy for Metastatic Spinal Cord Compression: Final Results of the PRE-MODE Trial. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):780–9. doi: 10.1016/j.ijrobp.2019.11.401. PMID: 31812719. [PubMed: 31812719] [CrossRef]
126.: Rades D, Huttenlocher S, Bajrovic A, et al. Surgery followed by radiotherapy versus radiotherapy alone for metastatic spinal cord compression from unfavorable tumors. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e861–8. doi: 10.1016/j.ijrobp.2010.11.056. PMID: 21277114. [PubMed: 21277114] [CrossRef]
127.: Rades D, Stalpers LJ, Veninga T, et al. Spinal reirradiation after short-course RT for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):872–5. doi: 10.1016/j.ijrobp.2005.03.034. PMID: 15939549. [PubMed: 15939549] [CrossRef]
128.: Romano KD, Trifiletti DM, Bauer-Nilsen K, et al. Clinical outcomes of helical conformal versus nonconformal palliative radiation therapy for axial skeletal metastases. Pract Radiat Oncol. 2017 Nov–Dec;7(6):e479–e87. doi: 10.1016/j.prro.2017.04.002. PMID: 28666907. [PubMed: 28666907] [CrossRef]
129.: Sayed MM, Abdel-Wanis ME, El-Sayed MI. Single fraction compared with multiple fraction re-irradiations in patients with painful bone metastases. Journal of Cancer Science and Therapy. 2013;5(2):089–93. doi: 10.4172/1948-5956.1000190. [CrossRef]
130.: Sohn S, Chung CK, Sohn MJ, et al. Radiosurgery Compared with External Radiation Therapy as a Primary Treatment in Spine Metastasis from Hepatocellular Carcinoma : A Multicenter, Matched-Pair Study. J Korean Neurosurg Soc. 2016 Jan;59(1):37–43. doi: 10.3340/jkns.2016.59.1.37. PMID: 26885284. [PMC free article: PMC4754585] [PubMed: 26885284] [CrossRef]
131.: Townsend PW, Rosenthal HG, Smalley SR, et al. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J Clin Oncol. 1994 Nov;12(11):2345–50. doi: 10.1200/jco.1994.12.11.2345. PMID: 7669102. [PubMed: 7669102] [CrossRef]
132.: Valeriani M, Scaringi C, Blasi L, et al. Multifraction radiotherapy for palliation of painful bone metastases: 20 Gy versus 30 Gy. Tumori. 2015 May–Jun;101(3):318–22. doi: 10.5301/tj.5000286. PMID: 25908049. [PubMed: 25908049] [CrossRef]
133.: van de Ven S, van den Bongard D, Pielkenrood B, et al. Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort. Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):39–47. doi: 10.1016/j.ijrobp.2019.12.041. PMID: 32007565. [PubMed: 32007565] [CrossRef]
134.: Wang J, Cao C, Yin H, et al. Efficacies of 89Sr and combination treatments with regional extra-beam radiotherapy for cancer patients with multiple bone metastasis. The Chinese-German Journal of Clinical Oncology. 2010;9(9):536–8. doi: 10.1007/s10330-010-0674-6. [CrossRef]
135.: Wolanczyk MJ, Fakhrian K, Hermani H, et al. Radiotherapy, bisphosphonates and surgical stabilization of complete or impending pathologic fractures in patients with metastatic bone disease. Journal of Cancer. 2016;7(1):121–4. doi: 10.7150/jca.13377. PMID: 26722368. [PMC free article: PMC4679389] [PubMed: 26722368] [CrossRef]
136.: Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1744–8. doi: 10.1016/j.ijrobp.2011.02.040. PMID: 21596489. [PMC free article: PMC4034682] [PubMed: 21596489] [CrossRef]
137.: Zhang C, Wang G, Han X, et al. Comparison of the therapeutic effects of surgery combined with postoperative radiotherapy and standalone radiotherapy in treating spinal metastases of lung cancer. Clin Neurol Neurosurg. 2016 Feb;141:38–42. doi: 10.1016/j.clineuro.2015.12.011. PMID: 26731462. [PubMed: 26731462] [CrossRef]
138.: Aids to the Examination of the Peripheral Nervous System: Memorandum No. 45. London, UK: Medical Research Council; 1976. https://mrc.ukri.org/documents/pdf/aids-to-the-examination-of-the-peripheral-nervous-system-mrc-memorandum-no-45-superseding-war-memorandum-no-7/. .
139.: Tomita T, Galicich JH, Sundaresan N. Radiation therapy for spinal epidural metastases with complete block. Acta Radiol Oncol. 1983;22(2):135–43. doi: 10.3109/02841868309134353. PMID: 6310968. [PubMed: 6310968] [CrossRef]
140.: Baskin DS. Spinal cord injury. In: Evans RW, ed Neurology and Trauma. Philadelphia, PA: WB Saunders; 1996:276–99.
141.: Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005 May 20;23(15):3366–75. doi: 10.1200/jco.2005.04.754. PMID: 15908648. [PubMed: 15908648] [CrossRef]
142.: Rades D, Veninga T, Stalpers LJ, et al. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol. 2007 Jan 1;25(1):50–6. doi: 10.1200/jco.2006.08.7155. PMID: 17194905. [PubMed: 17194905] [CrossRef]
143.: Rades D, Lange M, Veninga T, et al. Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):524–30. doi: 10.1016/j.ijrobp.2009.10.073. PMID: 20452136. [PubMed: 20452136] [CrossRef]
144.: Rades D, Fehlauer F, Stalpers LJ, et al. A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. Cancer. 2004 Dec 1;101(11):2687–92. doi: 10.1002/cncr.20633. PMID: 15493037. [PubMed: 15493037] [CrossRef]
145.: Correa VC, Lugo-Agudelo LH, Aguirre-Acevedo DC, et al. Individual, health system, and contextual barriers and facilitators for the implementation of clinical practice guidelines: a systematic metareview. Health Res Policy Syst. 2020 Jun 29;18(1):74. PMID: Pmc7322919. [PMC free article: PMC7322919] [PubMed: 32600417]
146.: Fischer F, Lange K, Klose K, et al. Barriers and Strategies in Guideline Implementation-A Scoping Review. Healthcare (Basel). 2016 Jun 29;4(3) PMID: Pmc5041037. [PMC free article: PMC5041037] [PubMed: 27417624]
147.: Bierbaum M, Rapport F, Arnolda G, et al. Clinicians’ attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature. Implement Sci. 2020 May 27;15(1):39. PMID: Pmc7251711. [PMC free article: PMC7251711] [PubMed: 32460797]
148.: Rauh S, Arnold D, Braga S, et al. Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions. ESMO Open. 2018;3(5):e000385. PMID: Pmc6069906. [PMC free article: PMC6069906] [PubMed: 30094071]
149.: Kalies H, Schöttmer R, Simon ST, et al. Critical attitudes and beliefs towards guidelines amongst palliative care professionals - results from a national survey. BMC Palliat Care. 2017 Mar 21;16(1):20. PMID: Pmc5359819. [PMC free article: PMC5359819] [PubMed: 28327170]
150.: Shakespeare TP, Lu JJ, Back MF, et al. Patient preference for radiotherapy fractionation schedule in the palliation of painful bone metastases. J Clin Oncol. 2003 Jun 1;21(11):2156–62. [PubMed: 12775741]
151.: Szumacher E, Llewellyn-Thomas H, Franssen E, et al. Treatment of bone metastases with palliative radiotherapy: patients’ treatment preferences. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1473–81. [PubMed: 15817353]
152.: Hahn C, Kavanagh B, Bhatnagar A, et al. Choosing wisely: the American Society for Radiation Oncology’s top 5 list. Pract Radiat Oncol. 2014 Nov–Dec;4(6):349–55. doi: 10.1016/j.prro.2014.06.003. PMID: 25407853. [PubMed: 25407853] [CrossRef]
153.: The American Academy of Hospice and Palliative Medicine Task Force. Five Things Physicians and Patients Should Question. Choosing Wisely. American Board of Internal Medicine Foundation. Released February 21, 2013; Revised January 14, 2021; Last reviewed 2022. Access at: https://www.choosingwisely.org/societies/american-academy-of-hospice-and-palliative-medicine/.
154.: Dennstädt F, Treffers T, Iseli T, et al. Creation of clinical algorithms for decision-making in oncology: an example with dose prescription in radiation oncology. BMC Med Inform Decis Mak. 2021 Jul 12;21(1):212. PMID: Pmc8274051. [PMC free article: PMC8274051] [PubMed: 34247596]
155.: Rotenstein LS, Kerman AO, Killoran J, et al. Impact of a clinical pathway tool on appropriate palliative radiation therapy for bone metastases. Pract Radiat Oncol. 2018 Jul–Aug;8(4):266–74. [PubMed: 29429920]
156.: Alcorn SR, Elledge CR, LaVigne AW, et al. Improving providers’ survival estimates and selection of prognosis- and guidelines-appropriate treatment for patients with symptomatic bone metastases: Development of the Bone Metastases Ensemble Trees for Survival Decision Support Platform. J Eval Clin Pract. 2022 Aug;28(4):581–98. [PubMed: 35090073]
157.: Beriwal S, Rajagopalan MS, Flickinger JC, et al. How effective are clinical pathways with and without online peer-review? An analysis of bone metastases pathway in a large, integrated National Cancer Institute-Designated Comprehensive Cancer Center Network. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1246–51. [PubMed: 22245207]
158.: Gebhardt BJ, Rajagopalan MS, Gill BS, et al. Impact of dynamic changes to a bone metastases pathway in a large, integrated, National Cancer Institute-designated comprehensive cancer center network. Pract Radiat Oncol. 2015 Nov–Dec;5(6):398–405. [PubMed: 26432676]
159.: Grant SR, Smith BD, Pandey P, et al. Does a Custom Electronic Health Record Alert System Improve Physician Compliance With National Quality Measures for Palliative Bone Metastasis Radiotherapy? JCO Clin Cancer Inform. 2021 Jan;5:36–44. [PubMed: 33411621]
160.: Booth M, Summers J, Williams MV. Audit reduces the reluctance to use single fractions for painful bone metastases. Clin Oncol (R Coll Radiol). 1993;5(1):15–8. [PubMed: 7678748]
161.: Donati CM, Nardi E, Galietta E, et al. An Intensive Educational Intervention Significantly Improves the Adoption of Single Fractionation Radiotherapy in Uncomplicated Bone Metastases. Clin Med Insights Oncol. 2021;15:11795549211027148. PMID: Pmc8312156. [PMC free article: PMC8312156] [PubMed: 34366683]
162.: Olson R, Chan M, Minhas N, et al. Programmatic Comparison and Dissemination of an Audit of Single-fraction Radiation Therapy Prescribing Practices for Bone Metastases is Associated with a Meaningful and Lasting Change in Practice on a Population Level. Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):325–9. [PubMed: 29902558]
163.: Olson RA, Tiwana M, Barnes M, et al. Impact of Using Audit Data to Improve the Evidence-Based Use of Single-Fraction Radiation Therapy for Bone Metastases in British Columbia. Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):40–7. [PubMed: 26281828]
164.: Shahhat S, Hanumanthappa N, Chung YT, et al. Do Coordinated Knowledge Translation Campaigns Persuade Radiation Oncologists to Use Single-Fraction Radiation Therapy Compared With Multiple-Fraction Radiation Therapy for Bone Metastases? Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):365–73. [PubMed: 32890661]
165.: Walker GV, Shirvani SM, Borghero Y, et al. Palliation or Prolongation? The Impact of a Peer-Review Intervention on Shortening Radiotherapy Schedules for Bone Metastases. J Oncol Pract. 2018 Aug;14(8):e513–e6. [PubMed: 30059272]
166.: Kim JO, Hanumanthappa N, Chung YT, et al. Does dissemination of guidelines alone increase the use of palliative single-fraction radiotherapy? Initial report of a longitudinal change management campaign at a provincial cancer program. Curr Oncol. 2020 Aug;27(4):190–7. PMID: Pmc7467795. [PMC free article: PMC7467795] [PubMed: 32905177]
167.: Jaworski EM, Yin H, Griffith KA, et al. Contemporary Practice Patterns for Palliative Radiation Therapy of Bone Metastases: Impact of a Quality Improvement Project on Extended Fractionation. Pract Radiat Oncol. 2021 Nov–Dec;11(6):e498–e505. [PubMed: 34048938]
168.: Kapadia NS, Brooks GA, Landrum MB, et al. Association of the Oncology Care Model With Value-Based Changes in Use of Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):39–46. [PubMed: 35150787]
169.: Yu JB, Pollack CE, Herrin J, et al. Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014. Am J Clin Oncol. 2019 Jun;42(6):493–9. PMID: Pmc6538429. [PMC free article: PMC6538429] [PubMed: 31033511]
170.: Skamene S, Agarwal I, Makar M, et al. Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among patients with bone metastases. Ann Palliat Med. 2018 Apr;7(2):186–91. doi: 10.21037/apm.2017.11.02. PMID: 29307209. [PubMed: 29307209] [CrossRef]
171.: van den Hout WB, van der Linden YM, Steenland E, et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst. 2003 Feb 5;95(3):222–9. doi: 10.1093/jnci/95.3.222. PMID: 12569144. [PubMed: 12569144] [CrossRef]
172.: Fischer-Valuck BW, Baumann BC, Apicelli A, et al. Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospital-based analysis of patterns of care, RT fractionation scheme, and overall survival. Cancer Med. 2018 Sep;7(9):4240–50. doi: 10.1002/cam4.655. Epub 2018 Aug 17. [PMC free article: PMC6144149] [PubMed: 30120817] [CrossRef]
173.: Cheon PM, Wong E, Thavarajah N, et al. A definition of “uncomplicated bone metastases” based on previous bone metastases radiation trials comparing single-fraction and multi-fraction radiation therapy. J Bone Oncol. 2015 Mar;4(1):13–7. doi: 10.1016/j.jbo.2014.12.001. PMID: 26579484. [PMC free article: PMC4620946] [PubMed: 26579484] [CrossRef]
174.: Chow R, Hoskin P, Chan S, et al. Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. Radiother Oncol. 2017 Mar;122(3):323–31. doi: 10.1016/j.radonc.2016.12.031. PMID: 28089482. [PubMed: 28089482] [CrossRef]
175.: Chow R, Hoskin P, Hollenberg D, et al. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. Ann Palliat Med. 2017 Apr;6(2):125–42. doi: 10.21037/apm.2016.12.04. PMID: 28249544. [PubMed: 28249544] [CrossRef]
176.: Chow R, Hoskin P, Schild SE, et al. Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. Radiother Oncol. 2019 Dec;141:56–61. doi: 10.1016/j.radonc.2019.06.037. PMID: 31445837. [PubMed: 31445837] [CrossRef]
177.: Migliorini F, Eschweiler J, Trivellas A, et al. Better pain control with 8-gray single fraction palliative radiotherapy for skeletal metastases: a Bayesian network meta-analysis. Clin Exp Metastasis. 2021 Apr;38(2):197–208. doi: 10.1007/s10585-020-10067-7. PMID: 33559808. [PMC free article: PMC7987640] [PubMed: 33559808] [CrossRef]
178.: Spencer KL, van der Velden JM, Wong E, et al. Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases. J Natl Cancer Inst. 2019 Oct 1;111(10):1023–32. doi: 10.1093/jnci/djz101. PMID: 31119273. [PMC free article: PMC6792073] [PubMed: 31119273] [CrossRef]
179.: Chow E, Hoskin P, Mitera G, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1730–7. doi: 10.1016/j.ijrobp.2011.02.008. PMID: 21489705. [PubMed: 21489705] [CrossRef]
180.: U.S. Department of Health and Human Services. Office of Disease Prevention and Promotion. Social Determinants of Health. Healthy People 2030. https://health.gov/healthypeople/objectives-anddata/social-determinants-health.
181.: Whitman A, De Lew N, Chappel A, et al. Addressing Social Determinants of Health: Examples of Successful Evidence-Based Strategies and Current Federal Efforts. Office of the Assistant Secretary for Planning and Evaluation (ASPE), Health and Human Services. April 1, 2022. https://aspe.hhs.gov/reports/sdoh-evidence-review.
182.: Dinh TT, Ford E, Halasz LM, et al. National Quality Improvement Participation Among US Radiation Oncology Facilities: Compliance with Guideline-Concordant Palliative Radiation Therapy for Bone Metastases. Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):564–71. doi: 10.1016/j.ijrobp.2020.04.047. PMID: 32407931. [PubMed: 32407931] [CrossRef]
183.: Saletti P, Sanna P, Gabutti L, et al. Choosing wisely in oncology: necessity and obstacles. ESMO Open. 2018;3(5):e000382. doi: 10.1136/esmoopen-2018-000382. PMID: 30018817. [PMC free article: PMC6045771] [PubMed: 30018817] [CrossRef]
184.: van der Velden J, Willmann J, Spalek M, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol. 2022 Aug;173:197–206. doi: 10.1016/j.radonc.2022.05.024. PMID: 35661676. [PubMed: 35661676] [CrossRef]
185.: Maroongroge S, Wallington DG, Taylor PA, et al. Geographic Access to Radiation Therapy Facilities in the United States. Int J Radiat Oncol Biol Phys. 2022 Mar 1;112(3):600–10. doi: 10.1016/j.ijrobp.2021.10.144. PMID: 34762972. [PubMed: 34762972] [CrossRef]
186.: Boyce-Fappiano D, Elibe E, Schultz L, et al. Analysis of the Factors Contributing to Vertebral Compression Fractures After Spine Stereotactic Radiosurgery. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):236–45. doi: 10.1016/j.ijrobp.2016.09.007. PMID: 28068232. [PubMed: 28068232] [CrossRef]
187.: Sahgal A, Atenafu EG, Chao S, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013 Sep 20;31(27):3426–31. doi: 10.1200/jco.2013.50.1411. PMID: 23960179. [PMC free article: PMC6076012] [PubMed: 23960179] [CrossRef]

Bookshelf ID: NBK595904

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Skelly AC, Chang E, Bordley J, et al. Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Aug. (Comparative Effectiveness Review, No. 265.) 5, References.
PDF version of this title (9.9M)